ICCC Q1 2022 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+46.1% YoY

Gross Profit

$3M51.7% margin

Operating Income

$570,6099.5% margin

Net Income

$513,2878.6% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

+10.2%

Cash Flow

Operating Cash Flow

$638,535

Free Cash Flow

-$168,961

Stock-Based Comp.

$54,093

Balance Sheet

Total Assets

$47M

Total Liabilities

$13M

Stockholders' Equity

$33M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+46.1%
Gross Profit	$3M	$2M	+93.7%
Operating Income	$570,609	-$374,625	+252.3%
Net Income	$513,287	-$441,303	+216.3%